Revumenib Revises the Treatment Landscape for KMT2A-r Leukemia

J Clin Oncol. 2025 Jan;43(1):85-88. doi: 10.1200/JCO-24-01265. Epub 2024 Nov 7.

Authors

Emily B Heikamp^{1

2}, Scott A Armstrong^{1

2}

Affiliations

¹ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
² Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA.

PMID: 39509656
DOI: 10.1200/JCO-24-01265

No abstract available

Grants and funding